Compare Rent the Runway Inc (RENT) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rent the Runway Inc vs TG Therapeutics Inc — how do they compare? Rent the Runway Inc trades at $2.81 (market cap $107.97M), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: TG Therapeutics Inc is far larger — about 79× Rent the Runway Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Rent the Runway Inc nearer its low. Which is the better fit depends on your goals.
| RENT | TGTX | |
|---|---|---|
Market Cap | $107.97M | $8.53B |
Sector | Consumer Cyclical | Health |
52-Week High | $9.39 | $59.06 |
52-Week Low | $3.01 | $26.94 |
Enterprise Value | $268.07M | $8.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RENT trades at $3.2, down 15.9% in 24 hours, with a bullish technical signal from moving averages. The company reported Q1 2026 EPS of -$0.04, beating expectations, but net income remains negative at -$69.9M for 2025. Revenue grew to $306.2M, with a high gross margin of 73.81%, while debt-to-asset ratio stands at 139.62%, indicating significant leverage. Analyst consensus is mixed, with 42% buy ratings and no sell recommendations.
Outlook hinges on debt management and path to profitability; opportunities include revenue growth and low P/E of 0.42, but risks involve high liabilities and inconsistent earnings. The stock faces pressure from negative equity and cash flow challenges, requiring careful monitoring of upcoming Q2 2026 results on September 11, 2026.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Rent the Runway Inc
Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe, or buy designer apparel and accessories.
Read more on RENT →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
